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Cerebral malaria (CM) is a serious complication of Plasmodium
falciparum infection associated with cerebral vasculopathy, high mortal-
ity, and risk of neurological sequelae. In humanCM, infected RBCs adhere
to the brain endothelium and occlude the cerebral blood vessels causing
cerebral vascular damage, impaired perfusion, vasospasms, vasocon-
striction, and inﬂammation. Vasoactive factors, including endothelin
(ET-1), have become increasingly important in the pathogenesis of
CM. We previously demonstrated that antagonism of the ET-1 type A
receptor (ETA) improved survival and attenuated brain hemorrhage in
murine CM. In this study we tested the hypothesis that ET-1 contributes
to CNS inﬂammation and BBB disruption in experimental CM (ECM)
via its actions on ETA. To test this hypothesis we used our model
of Plasmodium berghei ANKA (PbA) infection of C57BL/6 mice. PbA-
infection resulted in activation of monocytic CNS cells, microglia, which
are important in inﬂammation. ECMwas also associatedwith an increase
in brain microvascular endothelial cell activation which is critical for
leukocyte adhesion. Treatment of PbA-infected mice with ETA receptor
antagonists attenuated the increase in microglial and endothelial cell
activation, suggesting that ET-1 contributes to CNS inﬂammation during
ECM. Furthermore, leakage of Evans blue bound-albumin into the brain
was reduced in ECMmice receiving ETA receptor antagonism, providing
further support that disruption of the BBB and inﬂammation during ECM
result, in part, from increases in ET-1 and its actions on the ETA receptor.
Together theseﬁndings illustrate a role for ET-1 in the immunopathology
and vasculopathy associated with ECM, and highlight the peptide as a
potential target for adjunctive therapy for the protection of neurological
function in patients with CM.
doi:10.1016/j.lfs.2013.12.045
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Sepsis, a heterogeneous class of syndromes, is associated with the
development of progressive damage in multiple organs. The path-
ogenesis of sepsis-induced myocardial dysfunction is still not fully
understood. The present study examined the alteration of key angio-
genic signaling pathway mediated by the vascular endothelial growth
factor (VEGF) in sepsis heart and the effects of dual endothelin (ET)
antagonism on it. Normal male Wistar rats at age 8 wks were ad-
ministeredwith lipopolysaccharide (LPS: 15 mg/kg) and then sacriﬁced
at different time points (1 h, 3 h, 6 h and 10 h). Some rats without
LPS administration was considered as the control group. Some of
the LPS-administered rats were treated with dual endothelin blocker
(SB209670, 1 mg/kg body weight) for 6 h and then sacriﬁced. Admin-
istration of LPS resulted in increases in the serum levels of TNF-alpha
(maximum at 1 h after LPS, 1200-fold compared to control rats), and
ET-1 (maximum at 3 h after LPS, 25-fold compared to control rats). At
6 h after LPS administration, we found decreased percent of fractional
shortening in the heart. The expression of VEGF, and its downstream
angiogenic signaling molecules namely eNOS and NO, was signiﬁcantly
increased in heart tissues after LPS administration compared to the
control group which was also accompanied by increased cardiac ET-1
level. Dual endothelin blockade for 6 h further upregulated the VEGF
angiogenic signaling in endotoxemic heart.
doi:10.1016/j.lfs.2013.12.046
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Purpose: Endothelin-1 (ET-1) is overexpressed in breast carcino-
mas, while circulating levels of its precursor (Big ET-1) have also
been found elevated. In the present study, we evaluated plasma ET-1
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and Big ET-1 levels, and tissue expression of ET-1 in patients with
ductal carcinoma of the breast. Methods: Peripheral venous blood
samples were collected prior to diagnostic biopsy from women with
suspicious non-palpable mammographic lesions. Plasma ET-1 and Big
ET-1 levels were determined in 30 patients with IDC, 30 with DCIS and
30 with benign lesions (controls), by performing ELISA. ET-1 and VEGF
tissue expression was immunohistochemically determined. Potential
correlationswith histological grade, hormone receptor status, Her2/neu
ampliﬁcation, tumor size, lymph node involvement and disease stage
were investigated in IDC. Results: Big ET-1 plasma levels were signif-
icantly higher in IDC and DCIS patients compared to controls (p b 0.001
and p b 0.01, respectively). No signiﬁcant differences in ET-1 levels
were observed between the three groups. Moderate to strong IHC
staining for ET-1 was observed in 3/29 and 7/23 IDC and DCIS patients,
respectively. VEGF was signiﬁcantly expressed in 8/27 and 8/23 IDC
and DCIS patients, respectively. In IDC, plasma and tissue expression
of ET-1 and plasma expression of Big ET-1 did not correlate with any of
the analyzed clinicopathological characteristics or VEGF tissue expres-
sion. Conclusions: Plasma levels of Big ET-1 were a more sensitive
indicator of ET-1 deregulation than those of ET-1 in our study. Our
results support the potential clinical application of Big ET-1 as a breast
cancer biomarker.
doi:10.1016/j.lfs.2013.12.047
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Background: Endothelin-1 (ET-1) acts via two G-protein-coupled
receptors, ETA and ETB. Overexpressed ET-1 and ETA in colorectal
cancer (CRC) promote tumour growth and progression. Aim: To
investigate (1) ETA and ETB distribution in normal and cancer tissues
from patients with CRC and (2) determine ETA and ETB localisation to
cell types and tissue structures. Methods: ETA and ETB distribution was
determined using in vitro autoradiographywith competitive inhibition,
using receptor antagonists (BQ123, ZD4054, BQ788) on normal and
cancer tissues resected from patients with CRC (N= 8). Immunohis-
tochemistry (IHC) conﬁrmed ETA and ETB expression and identiﬁed
associated cells/structures. ETA distribution was also investigated by
quantum dots (QDs) conjugated to BQ123 (ETA-antagonist). Results: In
normal bowel epithelium, ETA was observed closer to the luminal
surface and ETB towards the muscularis mucosa/lamina propria. There
was greater ETA than ETB binding in CRC. Both cancer and normal
tissues demonstrated strongest binding to stromal cells, particularly
ﬁbroblasts (IHC). QD-BQ123 demonstrated an ETA punctate pattern in
stromal areas surrounding epithelial cells; and an ETA increase in CRC
compared to normal. Conclusions: ET-1 binds strongly to CRC stromal
structures, with ETA greater than ETB, and is consistent with ET-1
signalling contributing to tumourigenesis. Within normal tissue, dif-
ferential ETA and ETB distribution (luminal versus muscularis mucosa/
lamina propria) has not been reported previously. This may relate to
trophic, growth arrest and differentiation signalling. This study dem-
onstrates the effective, novel use of receptor-antagonist-conjugated
QDs; reveals possible ET-1 roles in normal tissue; and provides further
evidence for the potential therapeutic use of ETA antagonists as CRC
adjuvant treatment.
doi:10.1016/j.lfs.2013.12.048
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Background: The endothelin A receptor (ETA)mediates tumourigenic
signals in colorectal cancer (CRC). The ETA ligand, endothelin-1 (ET-1),
stimulates not only cancer cells but also surrounding ﬁbroblasts andmay
promote the creation of a supporting tumour stroma. Aim: To identify
ET-1 regulated genes associated with oncogenic pathways in colonic
ﬁbroblasts. Methods:Micro-array analysis following 4 h ET-1 stimulation
of colonic ﬁbroblast strains (isolated from patients undergoing resection
for CRC, n = 4) identiﬁed differentially expressed genes (n= 19) at
signiﬁcant levels. Three were investigated further: COLXI, AML-1, and
EGFR (collagen type-XI; acute myeloid leukemia-1; epidermal growth-
factor receptor). Quantitative RT-PCR (qRT-PCR) and immunoblotting
evaluated AML-1 and COLX expression levels, following treatment with
ET-1 and/or receptor antagonists (ETA: BQ123, ZD4054; ETB: BQ788).
ETA and ETB regulation of EGFR was investigated by gene silencing
(siRNA); these assays and ET-1 regulation of EGFR over 24 h were
evaluated by qRT-PCR. Results: ET-1 stimulated expression of AML-1 and
COLXI at both gene (N1.5-fold; p b 0.01) and protein (p b 0.05) levels;
stimulation was inhibited by ETA, but not by ETB, antagonism (AML-1:
75.1–77.1% by BQ123, ZD4054; COLXI: 65.1% by ZD4054; p b 0.05). EGFR
expression demonstrated a biphasic increase at 4 h and 24 h (3.8-fold;
4.5-fold). Silencing ETA, but not ETB, returned EGFR levels to control.
Conclusions: ETA antagonism has potential for targeting oncogenic
pathways: AML-1 is linked to c-Jun N-terminal kinase which inhibits
apoptosis/promotes proliferation; and abnormal TGF-β (transforming
growth-factor-beta) signalling. COLXI is linked to CRC tumourogenesis.
The ET-1-stimulated biphasic EGFR response and ETA antagonism have
not been reported before in CRC. These ﬁndings identify mechanisms
by which ETA promotes tumourigenesis and support addition of ZD4054
to existing EGFR antagonism therapy.
doi:10.1016/j.lfs.2013.12.049
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